On June 23, 2020 BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications reported that Richard Godfrey, CEO plans to present an overview of the Company at the upcoming Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq (Press release, BerGenBio, JUN 23, 2020, View Source [SID1234561386]). During the 30 minute presentation, participants will be able to submit questions electronically with answers provided at the discretion of the Company on an individual basis afterwards.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date and time: Thursday June 25, at 1:00 p.m. EDT (7:00 p.m. CET).

View and attend the event online: www.webcaster4.com/Webcast/Page/2408/35370

The presentation will also be made available on the Company’s website after the event has ended on 25 June at www.bergenbio.com/investors/presentations/